Short Interest in Curis, Inc. (CRIS) Expands By 101.8%

Curis, Inc. (NASDAQ:CRIS) was the target of a large growth in short interest during the month of January. As of January 12th, there was short interest totalling 2,872,369 shares, a growth of 101.8% from the December 29th total of 1,423,043 shares. Currently, 2.1% of the shares of the stock are short sold. Based on an average daily volume of 1,468,066 shares, the short-interest ratio is currently 2.0 days.

Curis (NASDAQ:CRIS) opened at $0.71 on Friday. Curis has a 1-year low of $0.67 and a 1-year high of $3.22. The company has a market cap of $114.81, a PE ratio of -1.77 and a beta of 1.63. The company has a current ratio of 5.15, a quick ratio of 5.15 and a debt-to-equity ratio of 1.24.

Curis (NASDAQ:CRIS) last announced its earnings results on Tuesday, November 7th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The business had revenue of $2.44 million for the quarter, compared to analysts’ expectations of $2.19 million. Curis had a negative net margin of 629.29% and a negative return on equity of 250.58%. The firm’s quarterly revenue was up 38.6% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($0.21) earnings per share. equities research analysts forecast that Curis will post -0.41 earnings per share for the current fiscal year.

In related news, CEO Ali Ph.D. Fattaey acquired 50,000 shares of the company’s stock in a transaction on Wednesday, November 15th. The stock was acquired at an average price of $1.06 per share, with a total value of $53,000.00. Following the acquisition, the chief executive officer now directly owns 115,890 shares of the company’s stock, valued at $122,843.40. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. 4.07% of the stock is owned by corporate insiders.

Several hedge funds and other institutional investors have recently made changes to their positions in CRIS. FNY Partners Fund LP raised its position in shares of Curis by 350.0% during the 3rd quarter. FNY Partners Fund LP now owns 67,500 shares of the biotechnology company’s stock valued at $100,000 after buying an additional 52,500 shares in the last quarter. OxFORD Asset Management LLP purchased a new stake in shares of Curis during the 2nd quarter valued at about $115,000. Voya Investment Management LLC raised its position in shares of Curis by 21.8% during the 2nd quarter. Voya Investment Management LLC now owns 68,138 shares of the biotechnology company’s stock valued at $129,000 after buying an additional 12,207 shares in the last quarter. Alliancebernstein L.P. raised its position in shares of Curis by 338.7% during the 2nd quarter. Alliancebernstein L.P. now owns 83,800 shares of the biotechnology company’s stock valued at $158,000 after buying an additional 64,700 shares in the last quarter. Finally, SG Americas Securities LLC raised its position in shares of Curis by 514.0% during the 4th quarter. SG Americas Securities LLC now owns 269,128 shares of the biotechnology company’s stock valued at $188,000 after buying an additional 225,295 shares in the last quarter. Hedge funds and other institutional investors own 55.22% of the company’s stock.

CRIS has been the subject of several research reports. Zacks Investment Research downgraded shares of Curis from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. Guggenheim initiated coverage on shares of Curis in a report on Monday, October 23rd. They set a “buy” rating and a $7.00 price objective for the company. Three investment analysts have rated the stock with a sell rating and three have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $6.50.

COPYRIGHT VIOLATION WARNING: “Short Interest in Curis, Inc. (CRIS) Expands By 101.8%” was originally reported by American Banking News and is the property of of American Banking News. If you are viewing this report on another domain, it was illegally copied and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be read at https://www.americanbankingnews.com/2018/01/28/short-interest-in-curis-inc-cris-expands-by-101-8.html.

Curis Company Profile

Curis, Inc is a biotechnology company seeking to develop and commercialize drug candidates for the treatment of cancers. The Company’s drug candidate is CUDC-907, an orally-available, small molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. CUDC-907 is an oral, dual inhibitor of Class I and II HDAC, as well as Class I PI3K enzymes.

Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply